Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depression (TRD) ...

This profile has not been claimed by the company. See reviews below to learn more or submit your own review. Compass is a real estate company with a network of offices across the United States. It ...